Obayashi to Acquire Multiplex in $526M Expansion Deal 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Trump Says Anthropic No Longer Seen as National Security Threat 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
BHP Shares Fall as Jansen Potash Project Costs Surge 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Amicus Therapeutics, Inc. (NASDAQ:FOLD) securities between March 19, 2015 and October 1, 2015.
Click here to learn about the case: http://docs.wongesq.com/FOLD-Info-Request-Form-939. There is no cost or obligation to you.
The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose that the United States Food and Drug Administration raised concerns about Amicus Therapeutics’ forthcoming new drug application for migalastat during their September 15, 2015 meeting.
On October 2, 2015, Amicus Therapeutics revealed it would no longer be in a position to submit its NDA in the fourth quarter of 2015. Upon this news, shares of Amicus Therapeutics fell 54% to close at $6.39 per share.
If you suffered a loss in Amicus Therapeutics you have until December 7, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/FOLD-Info-Request-Form-939.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
